Comparison of late-onset and non-late-onset systemic lupus erythematosus individuals in a real-world electronic health record cohort.

Late-onset systemic lupus erythematosus (LO-SLE) is defined as SLE diagnosed at age 50 years or later. Current studies on LO-SLE are small and have conflicting results. Using a large, electronic health record (EHR)-based cohort of SLE individuals, we compared demographics, disease characteristics, SLE-specific antibodies, and medication prescribing practices in LO ( = 123) vs. NLO-SLE ( = 402) individuals. The median age (interquartile range) at SLE diagnosis was 60 (56-67) years for LO-SLE and 28 (20-38) years for NLO-SLE. Both groups were predominantly female (85% vs. 91%, = 0.10). LO-SLE individuals were more likely to be White than NLO-SLE individuals (74% vs. 60%, = 0.005) and less likely to have positive dsDNA (39% vs. 58%, = 0.001) and RNP (17% vs. 32%, = 0.02) with no differences in Smith, SSA, and SSB. Autoantibody positivity declined with increasing age at SLE diagnosis. LO-SLE individuals were less likely to develop SLE nephritis (9% vs. 29%, < 0.001) and less likely to be prescribed multiple classes of SLE medications including antimalarials (90% vs. 95%, = 0.04), azathioprine (17% vs. 31%, = 0.002), mycophenolate mofetil (12% vs. 38%, < 0.001), and belimumab (2% vs. 8%, = 0.02). LO-SLE individuals may be less likely to fit an expected course for SLE with less frequent positive autoantibodies at diagnosis and lower rates of nephritis, even after adjusting for race. Understanding how age impacts SLE disease presentation could help reduce diagnostic delays in SLE.